Home/Filings/4/0001209191-23-042480
4//SEC Filing

Szekeres David Leslie 4

Accession 0001209191-23-042480

CIK 0000818033other

Filed

Jul 16, 8:00 PM ET

Accepted

Jul 17, 5:51 PM ET

Size

13.2 KB

Accession

0001209191-23-042480

Insider Transaction Report

Form 4
Period: 2023-07-13
Szekeres David Leslie
EVP, Chief Operating Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-07-13+4,56435,766 total
  • Exercise/Conversion

    Common Stock

    2023-07-13+1,25031,202 total
  • Exercise/Conversion

    Restricted Stock Units

    2023-07-131,2506,250 total
    Common Stock (1,250 underlying)
  • Tax Payment

    Common Stock

    2023-07-13$1.31/sh2,012$2,63633,754 total
  • Exercise/Conversion

    Restricted Stock Units

    2023-07-134,56423,372 total
    Common Stock (4,564 underlying)
Footnotes (4)
  • [F1]Restricted stock units convert into common stock on a one-for-one basis.
  • [F2]Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
  • [F3]The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).
  • [F4]The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Issuer

HERON THERAPEUTICS, INC. /DE/

CIK 0000818033

Entity typeother

Related Parties

1
  • filerCIK 0001602459

Filing Metadata

Form type
4
Filed
Jul 16, 8:00 PM ET
Accepted
Jul 17, 5:51 PM ET
Size
13.2 KB